Beta Bionics reported its first quarterly results as a public company. Sales jumped 145% to $20.4 million in the fourth quarter, coming in 2% above the consensus estimate of Wall Street analysts, Leerink Partners said in a Wednesday note to investors.
The performance was driven by nearly 4,100 new patient starts, a figure that is at the high end of the range the insulin pump company forecast in its initial public offering paperwork.
Leerink analysts named “better-than-expected pharmacy adoption” in the quarter as a positive for the company. Beta Bionics signed two large formulary contracts in late 2024 and early 2025, the analysts said, and expects the pharmacy channel to account for more than 20% of new patient starts this year.
“Expansion into the pharmacy will provide [Beta Bionics] with clear tailwinds to both the top and bottom line in the intermediate to long term,” the analysts said. “On that basis, we came away from today's call incrementally positive on the stock from a fundamental standpoint.”
Beat Bionics went public in January, raising $204 million in an upsized initial public offering.
Dexcom names chief commercial officer
Dexcom appointed Jon Coleman as chief commercial officer. Coleman spent 15 years at Masimo, rising to president of the patient monitoring company’s commercial teams. The position gave Coleman oversight of the consolidation of worldwide hospital sales, OEM, alternate care sales and clinical teams at Masimo.
Coleman has taken responsibility for the global commercial organization, including sales, marketing and customer experience, at Dexcom. The glucose biosensing company lowered its revenue forecast last year amid a restructuring of its salesforce, but Dexcom CEO Kevin Sayer said on an earnings call last month that the workers it has brought in have “now become more productive.”
Sayer has led the commercial team in recent months. Teri Lawver, who became Dexcom’s first chief commercial officer in January 2023, retired at the end of last year, and Sayer took on her responsibilities during the search for a permanent replacement.
Sibionics receives CE mark for CGM
Sibionics received a CE mark for its GS3 continuous glucose monitor. The Chinese medtech company claims the 2.9mm thick device is the world’s thinnest CGM. GS3 weighs 1.5g, Sibionics said, and has near field communication to allow uses to pair other devices by tapping them on the CGM. Dexcom’s G7 is 4.7mm thick and weighs 3.3g. Abbott’s Freestyle Libre 3 is 2.9mm thick and weighs 1g.
The company also highlighted its use of artificial intelligence to help users “better understand their glucose data” and “enable more effective self-management” of glucose levels. Sibionics said the CGM “can connect directly with Smartwatch and Receiver.” The company sells a watch, SiWatch, that connects to its CGM and allows users to view glucose data on their wrists.
Sibionics received a CE mark for an earlier version of its CGM, GS1, in 2023. The company, which employs 500 people across offices in China and California, said it became the first company to receive approval for a fingerstick-free CGM in China in 2021.
